GSK says RSV vac­cine trig­gered im­mune re­sponse in adults as young as 50 years old

GSK read out Phase III re­sults on Wednes­day sug­gest­ing that its res­pi­ra­to­ry syn­cy­tial virus vac­cine — cur­rent­ly ap­proved for the 60-and-old­er pop­u­la­tion — may trig­ger an im­mune re­sponse in slight­ly younger adults.

Arexvy’s im­mune re­sponse in adults ages 50 to 59 ap­peared non-in­fe­ri­or to that in adults 60 and old­er, in­clud­ing in a sub­group with un­der­ly­ing med­ical con­di­tions, ac­cord­ing to GSK. While RSV typ­i­cal­ly pos­es the great­est threat to in­fants and old­er adults, co­mor­bidi­ties such as COPD or asth­ma can put oth­ers at a height­ened risk.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.